论文部分内容阅读
格兰泰曲马多缓释片 1 0 0 ,1 5 0 ,2 0 0mg(TramalLong 1 0 0、1 5 0、2 0 0mg型 )上市后 ,我们对 31 5 3名使用此药的患者进行了售后调查研究。目的是为了遵守法律规定对产品进行调查和收集有关药物行为学的数据。主要侧重于药物的安全性和有效性的研究。格兰泰曲马多主要用于严重和极其严重的疼痛治疗。绝大多数报告显示 ,运动系统疾病所导致的疼痛占全部病例的 49.9% ,肿瘤占 2 4.3% ,外伤和骨折占1 0 .1 % ,神经性病变占 9.3%。接受治疗的患者的每日平均药量是 2 35 .7mg ,,通常分为两次给予。 82 .5 %的患者对此药疗效的评价是非常好和好。有不良反应的占全部患者的 6 .5 % ,其中大多数是典型的阿片药物类副作用 ,恶心占 3.4% ,头晕占1 .5 % ,眩晕占 1 .1 %。没有报道更为严重的和其它未报道过的副作用
Following the launch of the GTR Tramadol Sustained-release Tablets 100, 150, 200 mg (TramalLong 1 0 0,1 5 0,2 0 0 mg type), we evaluated 31 5 patients using this drug After-sales research. The purpose is to comply with legal requirements for product investigation and collection of data on the behavior of the drug. The main focus is on the safety and efficacy of drugs. Gruntti Tramadol is mainly used for severe and extremely serious pain treatment. The vast majority of reports show that 49.9% of all cases are attributable to motor system disease, 22.3% are tumors, 10.3% are trauma and fractures, and 9.3% are neurological lesions. The average daily dose of the treated patients is 2 35.7 mg and is usually divided into two doses. 82.5% of patients evaluated the efficacy of this drug is very good and good. The adverse reactions accounted for 6.5% of all patients, most of which were typical opioid side effects, with nausea accounting for 3.4%, dizziness accounting for 1.5% and dizziness accounting for 1.1%. No more serious and other unreported side effects have not been reported